
ONLINE SUPPLEMENT MATERIAL

Supplement figure 1. Myocardial infarction with coronary computed tomography angiography compared to other standard of care approaches in patients with acute chest pain. The size of central markers reflects the weight of each study.


	CCT	A	SO	:		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
ACRIN-PA 2016	11	907	5	461	21.3%	1.12 [0.39, 3.20]	
BEACON 2016	14	245	14	245	39.1%	1.00 [0.49, 2.05]	
CATCH 2015	2	285	7	291	10.4%	0.29 [0.06, 1.39]	
CT-COMPARE 2014	6	322	3	240	13.2%	1.49 [0.38, 5.90]	
CT-STAT 2011	1	361	5	338	5.8%	0.19 [0.02, 1.59]	
Goldstein 2007	0	99	0	98		Not estimable	
PERFECT 2016	2	198	1	197	4.6%	1.99 [0.18, 21.77]	
ROMICAT-II 2012	1	501	4	499	5.5%	0.25 [0.03, 2.22]	
Total (95% CI)		2918		2369	100.0%	0.82 [0.49, 1.39]	•
Total events	37		39				
Heterogeneity: Tau² =				P = 0.36	6); I² = 9%	1	0.01 0.1 1 10 100
Test for overall effect: 2	Z = 0.72 (1	P = 0.47	7)				Lower CCTA Lower SOC

CCTA coronary computed tomography angiography, SOC standard of care.


Supplement figure 2. Funnel plots for CCTA vs SOC for all-cause mortality.




Supplement figure 3. Funnel plots for CCTA vs SOC for myocardial infarction,




Supplement figure 4. Funnel plots for CCTA vs SOC for major adverse cardiovascular events,




Supplement figure 5. Funnel plots for CCTA vs SOC for invasive coronary angiography.




Supplement figure 6. Funnel plots for CCTA vs SOC for revascularization.




Supplement figure 7. Meta-regression MACE and age




Supplement figure 8. Meta-regression revascularization and age



Supplement figure 9. Meta-regression MACE and diabetes



Supplement figure 10. Meta-regression revascularization and diabetes



Supplement table 1. Revascularization used in the included studies

Study	Revascularization				
	PCI	CABG			
ACRIN PA(7,8)		Not Reported			
BEACON(9)	Yes	Yes			
CATCH(10,11)	Yes	Yes			
CT-COMPARE(12)	Yes	Yes			
CT-STAT(13)	Yes	Yes			
Goldstein et al(4)	Yes	Yes			
Nabi et al(14)		Not Reported			
PERFECT(15)	Yes	Yes			
PROSPECT(16)	Yes	Yes			
ROMICAT-II(17)	Yes	Yes			

CABG coronary artery bypass grafting surgery, PCI percutaneous coronary intervention

Supplement table 2. Inclusion and exclusion criteria of the trials*

Study	Inclusion Criteria	Exclusion Criteria
	Age >30 years, non-ischemic EKG,	Non-cardiac symptoms requiring
ACRIN PA(7,8)	TIMI score 0-2	admission, normal CCTA or ICA
		within 1 year
	Age men 30-75 years and women	BMI >40 kg/m², non-cardiac
BEACON(9)	30-80 years, negative cardiac	symptoms, need for urgent ICA,
	biomarkers	clinical instability
	Age >18 years, non-ischemic EKG,	Prior CABG, mental or physical
CATCH(10,11)	negative cardiac biomarkers,	conditions impairing follow up,
	planned for discharge within 24hrs	abnormal chest radiography
CT-COMPARE(12)	Non-ischemic EKG, negative	AF, severe reactive airway disease
C1-COMPARE(12)	cardiac biomarkers, TIMI score <4	
	Age >25 years, chest pain during	LVEF <45%, AF or markedly
CT-STAT(13)	the past 12 hrs, non-ischemic EKG,	irregular rhythm, BMI >39 kg/m²
C1-31A1(13)	negative cardiac biomarkers, TIMI	
	score ≤4	
	Age >25 years, chest pain during	LVEF <45%, AF or markedly
	the past 12 hrs, non-ischemic EKG,	irregular rhythm, BMI >39 kg/m²
Goldstein et al(4)	negative cardiac biomarkers, low	
	likelihood of infarction or	
	complications	

	Age > 18 years, negative cardiac	LVEF <45%, underlying
	biomarkers, hospitalized for chest	comorbidity limiting follow up,
Nabi et al(14)	pain awaiting MPI	duplicate emergency room visits,
		patient/physician refusal to
		participate
PERFECT(15)	Age > 45 years, non-ischemic EKG,	AF or markedly irregular rhythm
TERRIBET(13)	negative cardiac biomarkers	
PROSPECT(16)	Non-ischemic EKG, negative	CCTA, MPI, or ICA within 6
r ROSFECT(10)	cardiac biomarkers	months
	Age 40-74 years, chest pain that	BMI >40 kg/m², symptomatic
ROMICAT-II(17)	lasted >5 min and <24hrs, non-	asthma, non-sinus rhythm
KOMEAT-II(17)	ischemic EKG, negative cardiac	
	biomarkers	

^{*}Uniformly accepted exclusion criteria include pregnancy, renal failure, allergy to iodine contrast, and inability to obtain informed consent

AF atrial fibrillation, BMI body mass index, CABG coronary artery bypass grafting surgery, CCTA coronary computed tomography angiography, EKG electrocardiogram, ICA invasive coronary angiography, MPI myocardial perfusion imaging, LVEF left ventricular ejection fraction, TIMI Thrombolysis in Myocardial Infarction.

Supplement table 3. Repeat emergency department visits and hospitalizations in the included trials

Study	Follow	Repeat ED visits			Rep	eat Hospita	alization
	-up,	CCTA	SOC	P value	ССТА	SOC	P value
	months						
ACRIN PA(7,8)	12	36%	38%	N/A	16%	17%	N/A
BEACON(9)	1	5%	8 %	0.27	3%	6%	0.12
CATCH(10,11)	19	N/A	N/A	N/A	10%	12%	0.23
CT-	12	12.7%	10.0%	0.3	10.3%	10.8%	0.8
COMPARE(12)							
CT-STAT(13)	6	0.6%	1.3%	0.43	0	0	N/A
Goldstein et al(4)	6	8.1%*	8.1%*	1.0	1%	4.1%	0.21
Nabi et al(14)	7	N/A	N/A	N/A	N/A	N/A	N/A
PERFECT(15)	12	N/A	N/A	N/A	14%	16%	0.5
PROSPECT(16)	12	63%	57.5%	0.31	43%	49%	0.27
ROMICAT-II(17)	1	2.8%	3.8%	0.38	1.4%	1.4%	N/A

^{*=}emergency department and office visits

ED emergency department, CCTA coronary computed tomography angiography, SOC standard of care

Supplement table 4. Length of stay in the included trials

Study	CCTA, hours	SOC, hours	P value
ACRIN PA(7,8)	Median 18(7.6-27.2)	Median 24.8 (19.2-30.5)	N/A
BEACON(9)	Median 6.3 (4.8–11.1)	Median 6.3 (4.5–25.5)	0.80
CATCH(10,11)	N/A	N/A	N/A
CT-COMPARE(12)	Median 13.5 (11.2–15.7)	Median 19.7 (17.3–22.0)	0.003
CT-STAT(13)	N/A	N/A	N/A
Goldstein et al(4)	N/A	N/A	N/A
Nabi et al(14)	Mean 19.7±27.8	Mean 23.5±34.4	0.002
PERFECT(15)	Mean 48±40	Mean 49±48	0.80
PROSPECT(16)	Median 28.9 (11.0–48.4)	Median 30.4 (23.9–51.3)	0.057
ROMICAT-II(17)	Mean 23.2±37	Mean 30.8±28	<0.001
	Median 8.6 (6.4-27.6)	Median 26.7 (21.4-30.6)	

CCTA coronary computed tomography angiography, SOC standard of care

Supplement table 5. Cost of acute care in the included trials

Study	CCTA cost	SOC cost	P-Value
ACRIN PA(7,8)	N/A	N/A	N/A
BEACON(9)	Median €337 (337–932)	Median €511 (309–916)	<0.01
CATCH(10,11)	N/A	N/A	N/A
CT-	Median \$2,193 (1,997–	Median \$2,704 (2,555–	< 0.001
COMPARE(12)	2,389)	2,853)	
CT CTAT(12)	Median \$2,137 (1,660–	Median \$3,458 (2,900–	< 0.0001
CT-STAT(13)	3,077)	4,297)	
C 11 4 1 4 1/4)	Median \$1,586 (1,413–	Median \$1,872 (1,727–	< 0.001
Goldstein et al(4)	2,059)	2,069)	
Nabi et al(14)	Mean \$4,242±3,871	Mean \$5,104±3,703	0.006
PERFECT(15)	N/A	N/A	N/A
PROSPECT(16)	N/A	N/A	N/A
	Median \$1,946 (1,514-	Median \$2,809 (1,822-4,060)	0.65
ROMICAT-II(17)	4,164)	Mean \$4,060±5,452	
	Mean \$4,289±7,110		

CCTA coronary computed tomography angiography, SOC standard of care

Supplement table 6. Subgroup analysis comparing CCTA to SOC in patients evaluated in the emergency department.

Outcome	Studies	Patients	Pooled RR (95% CI)	\mathbf{I}^2
All-cause mortality	6	4,316	0.76[0.21, 2.8], p = 0.68	0%
Myocardial Infarction	6	4,316	0.90[0.53-1.55], p = 0.71	5%
MACE	6	4,316	1.16[0.79, 1.71], p = 0.44	0%
Invasive Coronary Angiography	6	4,316	1.36 [1.09, 1.69], p=0.006	0%
Revascularization	6	4,316	1.64[1.20, 2.26], p=0.002	0%

CI Confidence interval, MACE Major adverse cardiac events, RR Relative risk

Supplement table 7. Subgroup analysis comparing CCTA to SOC in the inpatient settings

Outcome	Studies	Patients	Pooled RR (95% CI)	\mathbf{I}^2
All-cause mortality	3	1,371	0.21[0.04, 1.20], p=0.08	0%
Myocardial Infarction	2	971	0.61[0.10, 3.81], p=0.60	42%
			_	
MACE	4	1,959	0.83[0.38, 1.80], p=0.63	54%
		,	3/1	
Invasive Coronary Angiography	4	1,959	1.35[0.82, 2.20], p=0.23	69%
		<i>y</i>	,	
Revascularization	4	1,959	2.04[1.10, 3.76], p=0.02	48%
10 vascarar izacion	¬	1,737	2.04[1.10, 3.70], p=0.02	70/0
				1

CI Confidence interval, MACE Major adverse cardiac events, RR Relative risk

Supplement Table 8. Coronary computed tomography angiography compared to other standard of care approaches in the acute settings, fixed effects model.

Outcome	Studies	Patients	Pooled RR (95% CI)	I^2
All-cause mortality	9	5,687	0.46 [0.18 – 1.18], p=0.11	0%
Myocardial Infarction	8	5,287	0.79 [0.50 – 1.24], p=0.31	9%
MACE	10	6,285	0.99 [0.74 – 1.32], p=0.93	26%
Invasive Coronary Angiography	10	6,285	1.33 [1.13 – 1.57], p=0.0006	33%
Revascularization	10	6,285	1.84 [1.44 – 2.36], p<0.00001	8%

CI Confidence interval, MACE Major adverse cardiac events, RR Relative risk

Supplement Table 9. Coronary computed tomography angiography compared to other standard of care approaches in the acute settings, sensitivity analysis. Results after excluding BEACON trial are shown.

Outcome	Studies	Patients	Pooled RR (95% CI)*	\mathbf{I}^2
All-cause mortality	8	5,197	0.38 [0.13 – 1.16], p=0.09	0%
Myocardial Infarction	7	4,797	0.70 [0.33 – 1.47], p=0.35	19%
MACE	9	5,795	0.92 [0.58 – 1.48], p=0.74	32%
Invasive Coronary Angiography	9	5,795	1.33 [1.04 – 1.70], p=0.02	40%
Revascularization	9	5,795	1.88 [1.40 – 2.52], p<0.0001	7%

^{*}Excluded BEACON trial.

CI Confidence interval, MACE Major adverse cardiac events, RR Relative risk